pa旗舰厅
中
繁
EN
pa旗舰厅:For Patients
pa旗舰厅:Investors
Careers
Contact
Home
About Us
pa旗舰厅:Our Story
pa旗舰厅:Leadership
pa旗舰厅:Board of Directors
pa旗舰厅:Jacobio people stories
pa旗舰厅:Platform & Pipeline
Platform
Pipeline
pa旗舰厅:Publications
pa旗舰厅:Partnership
News
pa旗舰厅:Company News
pa旗舰厅:Media Report
84
press releases in total
2024
Sep 20, 2024
Jacobio Pharma Received Pan-KRAS Inhibitor IND Approval from FDA
pa旗舰厅: [More]
Sep 15, 2024
Jacobio Pharma Presents Efficacy Data of Glecirasib in Combination with JAB-3312 with PD-L1 Expression Levels
pa旗舰厅: [More]
Aug 30, 2024
Jacobio Out-licensed KRAS G12C Inhibitor Glecirasib and SHP2 Inhibitor JAB-3312 to Allist in China
pa旗舰厅: [More]
Aug 12, 2024
Jacobio’s SHP2 Inhibitor JAB-3312 Published in Journal of Medicinal Chemistry
pa旗舰厅: [More]
Aug 7, 2024
Jacobio Completes First Patient Dosage in the Phase III Clinical Trial of JAB-3312 in Combination with Glecirasib
pa旗舰厅: [More]
Jul 26, 2024
Jacobio Completes First Patient Dosage of p53 Y220C Activator
pa旗舰厅: [More]
Jun 13, 2024
Jacobio Appoints Dr. Alan Xiao as Vice President of Clinical Pharmacology
pa旗舰厅: [More]
Jun 2, 2024
Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO
pa旗舰厅: [More]
May 21, 2024
Jacobio Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for Glecirasib
pa旗舰厅: [More]
May 10, 2024
Jacobio Announces China CDE Clearance for Phase III Clinical Trial of KRAS G12C Inhibitor Glecirasib in Patients with Colorectal Cancer
pa旗舰厅: [More]
May 6, 2024
Jacobio Announces the Submission of New Drug Application for Glecirasib
pa旗舰厅: [More]
May 1, 2024
Jacobio Pharma Announced its KRAS G12C Inhibitor Reached the Primary Endpoint
pa旗舰厅: [More]
Apr 26, 2024
Jacobio Pharma to Announce Two Oral Presentation at 2024 ASCO
pa旗舰厅: [More]
Apr 17, 2024
Jacobio Receives Orphan Drug Designations for Glecirasib for Pancreatic Cancer in the U.S.
pa旗舰厅: [More]
Apr 9, 2024
Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting
pa旗舰厅: [More]
Mar 28, 2024
Jacobio Pharma Announces 2023 Annual Results
pa旗舰厅: [More]
Mar 1, 2024
Jacobio Pharma Receives IND Approval for P53 Y220C Activator JAB-30355 in the U.S.
pa旗舰厅: [More]
Feb 18, 2024
Jacobio Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor
pa旗舰厅: [More]
Jan 20, 2024
Jacobio Pharma Presents Data of Glecirasib in Patients with Pancreatic Cancer and Other Solid Tumors at the 2024 ASCO GI
pa旗舰厅: [More]
2023
Dec 7, 2023
Jacobio Pharma to Present Data of KRAS G12C Inhibitor Glecirasib in Patients with Pancreatic Cancer and Other Solid Tumors at the 2024 ASCO GI
pa旗舰厅: [More]
Pages
«
‹
1
2
3
4
5
›
»
